Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).

Priyanka Sharma,Bruce F. Kimler,Anne O'Dea,Lauren Nye,Yen Y. Wang,Rachel Yoder,Lh Prochaska,Jamie L. Wagner,Amanda Leigh Amin,Kelsey E. Larson,Christa R. Balanoff,Manana Elia,Gregory James Crane,Sheshadri Madhusudhana,Marc Steven Hoffmann,Maureen Sheehan,Robert R. Rodriguez,Roy A. Jensen,Andrew K. Godwin,Qamar J. Khan

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).

2019

516Background: Addition of neoadjuvant carboplatin (Cb) to paclitaxel (T) followed by doxorubicin + cyclophosphamide (AC) improves pathologic complete response (pCR) rate compared to T/AC in TNBC. ...

Keywords:

Carboplatin
Oncology
Triple-negative breast cancer
Paclitaxel
Pathology
Internal medicine
Medicine
Docetaxel
complete response
Doxorubicin
Cyclophosphamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations